Loading stock dataβ¦
$21.65+0.47 (+2.22%)
SpyGlass Pharma, Inc.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | β | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$15.41Mβ | -$13.63M | β | -$7.42Mβ | -$7.75M |
| Net Income | -$13.82Mβ | -$12.56M | β | -$8.82Mβ | -$8.40M |
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and pr...
MongoDB downgraded, Block upgraded: Wall Street's top analyst calls
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index and the State Street
Health care stocks rose Friday afternoon, with the NYSE Health Care Index increasing 1.3% and the St